CompanyGraph
Roivant Sciences Ltd
ROIV · United Kingdom
Runs each drug program as its own separate company with its own money and its own FDA pathway.
Roivant Sciences builds each drug program as its own legally separate company — called a Vant — with its own management team, its own pool of capital, and its own FDA filings, so that a failure in one program cannot quietly drain funding from another that is still running. Because each Vant must raise and spend its own money, the teams inside them are accountable only to their own clinical data rather than to a parent deciding which programs to favor. Two shared platforms, Datavant for connecting patient data across hospital systems and Lokavant for optimizing trial sites, serve all the Vants from a single layer, so adding a new subsidiary does not require rebuilding the software — but it does require a fresh management team, fresh regulatory filings, and a fresh pool of capital that no other Vant can supply. That last point is where the whole structure is most exposed: if equity markets tighten and a Vant cannot raise money on its own, the parent cannot redirect funds from a healthier sibling without dissolving the legal separation that makes the model work in the first place.
How does this company make money?
When a drug candidate succeeds, pharmaceutical partners pay milestone fees and licensing fees tied to that progress. Datavant brings in subscription revenue from healthcare institutions that use its data-sharing platform. If any Vant's drug eventually wins full regulatory approval, that subsidiary could sell the drug directly and collect product revenue.
What makes this company hard to replace?
Datavant's data-sharing connections are already built into hospital systems, so replacing it would mean dismantling and rebuilding those integrations across many institutions. Lokavant's trial optimization tools have been trained on historical data specific to each therapeutic area, so a new provider would have to start that learning process from scratch. The management teams inside each Vant also carry deep expertise in their specific disease area — expertise that would not transfer to a traditional pharma partner.
What limits this company?
Each subsidiary must raise its own money from outside investors to fund its next round of clinical testing. When the stock market turns cold and investors pull back from early-stage biotech, an individual Vant can run out of runway with no legal way to borrow from a sibling that happens to be better funded.
What does this company depend on?
The company cannot operate without FDA Investigational New Drug applications for each Vant's drug candidates, Datavant's healthcare data platform for finding eligible trial patients, contract research organizations that run the physical clinical trials across multiple sites, specialized biologics manufacturing facilities that produce the actual drugs, and access to equity capital markets to keep each pre-revenue subsidiary funded.
Who depends on this company?
Autoimmune disease patients enrolled in Immunovant's batoclimab trials would lose access to that drug if development stopped. Clinical research sites use Lokavant's platform to find and recruit patients more efficiently — without it, that process slows down. Healthcare systems across institutions rely on Datavant's data-sharing infrastructure to support clinical decisions.
How does this company scale?
Datavant and Lokavant can absorb additional Vants without much extra cost — the software does not need to be rebuilt for each new subsidiary. What does not get cheaper is everything else: every new Vant needs its own clinical development team, its own regulatory filings, and its own pool of capital, none of which can be shared or automated without dismantling the focused-execution model.
What external forces can significantly affect this company?
Changes to FDA expedited approval pathways could speed up or slow down several Vants at once, since the subsidiaries all face the same regulatory environment. Healthcare data privacy regulations could restrict what Datavant is allowed to share across hospital systems. And swings in equity market conditions directly threaten the ability of individual Vants to raise the money they need to keep their programs alive.
Where is this company structurally vulnerable?
If equity markets shut off access to capital for early-stage biotech companies, an individual Vant could run out of money before its next clinical milestone. The parent cannot step in and redirect cash from a healthy Vant to a struggling one — doing so would dissolve the legal separation that makes the whole structure work in the first place.